Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Taps CMM to Help Develop Women's Health Biomarkers

NEW YORK (GenomeWeb News) – Qiagen will use a database and software, as well as clinical samples, from the Center for Molecular Medicine in research aimed at developing biomarkers for breast cancer and other women’s health issues, the company said today.
 
The agreement gives Qiagen access to CMM’s XenoBase software and database, which was developed by CMM’s partner, the Van Andel Research Institute, to “identify clinically actionable associations between diseases, biomarkers and treatments,” the company said. 
 
After the initial biomarker research is completed, Qiagen also may use CMM’s genomics and proteomics laboratory services to develop and validate molecular diagnostic tests.
 
Financial terms of the agreement were not released.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.